ClinicalTrials.gg
RecruitingNCT06696235REDUCE-ECMOUpdated Jan 5, 2026

Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator

A Phase 4 interventional study of Early initiation of continuous renal replacement therapy and Standard initiation of continuous renal replacement therapy in Cardiogenic Shock and Acute Kidney Injury, sponsored by Samsung Medical Center. Recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of — 8 open to participants now, 8 under way, none of them phase 3. Shock, Cardiogenic · Korea, Republic of.

Planned enrollment
4th of 10
408 · median 280
Started
2024
with 1 other
Phase 4
2 of 13
2 open now
Registered
10th of 13
by date
Lead sponsor
5 of 13
Samsung Medical Center

Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 10th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

8 of the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study was designed to compare the safety and efficacy of early continuous renal replacement therapy with standard continuous renal replacement therapy in the presence of acute kidney injury (stage 2 or greater acute kidney injury according to the KDIGO [The Kidney Disease: Improving Global Outcomes] classification) in patients with advanced cardiogenic shock on extracorporeal membrane oxygenation.

Read the detailed description

Patients with cardiogenic shock who are placed on extracorporeal membrane oxygenation devices often have increased afterload due to the retrograde arterial flow of the device, resulting in increased left ventricular filling pressures, and optimal full-load management in these patients may be important to improve prognosis. Previous observational studies have reported that the use of renal replacement therapy for full-load management in patients with cardiogenic shock on extracorporeal membrane oxygenation is effective and improves patient survival in cases of severe renal dysfunction when fluid volume reduction is maintained. However, to date, there have been no randomized controlled studies to identify the optimal timing of renal replacement therapy in patients with cardiogenic shock on extracorporeal membrane oxygenation.

03

Conditions studied

  • Cardiogenic Shock
  • Acute Kidney Injury

Keywords

  • Extracorporeal Membrane Oxygenator
  • Cardiogenic Shock
  • Acute Kidney Injury
  • Continuous Renal Replacement Therapy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must be at least 19 years of age.
  • Patients presented with CS (Society for Cardiovascular Angiography and Interventions [SCAI] Shock classification C, D or E) * who requiring VA-ECMO.
  • Classic CS (Stage C) was defined as the following criteria. A. Systolic blood pressure less than 90 mmHg for more than 30 min or catecholamines required to maintain pressure more than 90 mmHg during systole. B. Sign of pulmonary congestion

C. Sign of impaired organ perfusion with at least one of the following:

  1. altered mental status.
  2. cold, clammy skin and extremities.
  3. oliguria with urine output \< 30ml/h.
  4. serum lactate > 2.0 mmol/l.

    • SCAI Shock classification D is defined as failure to respond to initial interventions with clinical deterioration of classic CS or SCAI Shock classification E is defined as cardiac arrest with ongoing cardiopulmonary resuscitation requiring VA-ECMO
    • Patients in the first 48 hours of CS developing AKI with at least one criterion (Characteristic of the stage 2 AKI according to Kidney Disease: Improving Global Outcomes [KDIGO] classification)
    • A 2-fold or over increase in serum creatinine relative to baseline
    • A reduction in urine output of ≤0.5 ml/kg/h for ≥ 12 hours

Exclusion criteria

Exclusion Criteria:

  • Other causes of shock (hypovolemia, sepsis, obstructive shock).
  • Criteria mandating CRRT initiation: acute kidney injury prior to enrollment caused by any reason, at least one of the following criteria is met.
  • serum potassium > 6.5 mmol/L
  • serum potassium> 6.0 mmol/L persisting despite medical treatment.
  • metabolic acidosis (pH \< 7.15 and PaCO2 \< 35 mmHg or serum bicarbonate \< 12 mmol/L)
  • blood urea nitrogen level ≥100 mg/dL.
  • diuretics volume overload or pulmonary edema
  • Unwitnessed out-of-hospital cardiac arrest with persistent Glasgow coma scale \<8 after the return of spontaneous circulation.
  • Chronic kidney disease (CKD) with estimated (eGFR)\<30 mL/min/1.73m2 or end-stage kidney disease under dialysis
  • Kidney transplant within the past 365 days
  • Receipt of any RRT in the preceding 2 months
  • Known heparin intolerance.
  • Other severe concomitant disease with limited \< 6 months
  • Pregnancy or breastfeeding
  • Do not resuscitate wish.
  • Presence of a drug overdose or dialyzable toxin that necessitates RRT.
  • Presence or strong clinical suspicion of post-renal AKI duet to obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy or acute interstitial nephritis
  • Clinical decision by a responsible physician to immediately start RRT.
  • Clinical decision by a responsible physician to defer RRT.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
408 participants (estimated)

Study arms

  • Experimental
    Accelerated initiation of CRRT

    In the accelerated-strategy group, RRT is initiated as soon as possible and within 6 hours after patients have met full eligibility criteria.

    Device: Early initiation of continuous renal replacement therapy

  • Active comparator
    Standard initiation of CRRT

    Clinicians were discouraged from initiating RRT until the development of one or more of the following criteria. * Serum potassium \> 6.5 mmol/L * Serum potassium\> 6.0 mmol/L persisting despite medical treatment * Metabolic acidosis (pH \< 7.15 and PaCO2 \< 35 mmHg or serum bicarbonate \< 12 mmol/L) * Blood urea nitrogen level ≥100 mg/dL * Oliguria (≤0.3 ml/kg/hour) or anuria for 48h or more * Diuretics refractory fluid overload or pulmonary edema

    Device: Standard initiation of continuous renal replacement therapy

Interventions

  • DeviceEarly initiation of continuous renal replacement therapy

    Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.

  • DeviceStandard initiation of continuous renal replacement therapy

    Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.

06

What researchers measure

Primary outcomes

  1. all-cause mortality or RRT dependence

    Time frame: 90 days after patient enrollment

Secondary outcomes

  1. In-hospital mortality

    Time frame: Up to 30 days

  2. In-hospital cardiac mortality

    Time frame: Up to 30 days

  3. VA-ECMO weaning success

    Time frame: Up to 30 days

  4. Time to VA-ECMO weaning

    Time frame: Up to 30 days

  5. Critical limb ischemia

    Time frame: Up to 30 days

  6. Access site major bleeding

    Bleeding Academic Research Consortium \[BARC\] type 3-5

    Time frame: Up to 30 days

  7. CPC 3-5

    Cerebral Performance Category

    Time frame: Up to 30 days

  8. Length of intensive-care unit stay

    ICU Stay

    Time frame: Up to 30 days

  9. Length of hospital stay

    Hospital stay

    Time frame: Up to 30 days

  10. Duration of mechanical ventilation

    Mechanical Ventilation Maintenance

    Time frame: Up to 30 days

  11. Duration of RRT

    Renal Replacement Therapy

    Time frame: Up to 30 days

  12. all-cause mortality

    Time frame: 90 days & 12 months after patient enrollment

  13. cardiac mortality

    Time frame: 90 days & 12 months after patient enrollment

  14. Requirement of cardiac replacement therapy

    Left ventricular assisted device implantation or heart transplantation

    Time frame: 90 days & 12 months after patient enrollment

  15. re-hospitalization due to heart failure

    Time frame: 90 days & 12 months after patient enrollment

  16. re-hospitalization due to any cause

    Time frame: 90 days & 12 months after patient enrollment

  17. cerebrovascular accident

    ischemic or hemorrhagic

    Time frame: 90 days & 12 months after patient enrollment

  18. RRT dependence

    Time frame: 90 days & 12 months after patient enrollment

  19. Serum creatinine and eGFR

    Time frame: 90 days & 12 months after patient enrollment

  20. major bleeding (BARC type 3, or 5)

    Time frame: 90 days & 12 months after patient enrollment

  21. clinically meaningful bleeding (BARC type 2, 3, or 5)

    Time frame: 90 days & 12 months after patient enrollment

  22. Patients in the standard strategy group who received emergency RRT before 48 hours, according to criterion

    Time frame: Up to 48 hours

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 20, 2024
StartActual
Dec 31, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jun 30, 2029
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06696235
Responsible party
Jeong Hoon Yang (Professor, Samsung Medical Center) — Principal investigator
First posted
Nov 20, 2024
Start date
Dec 31, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Jan 5, 2026

Study contacts

Jeong Hoon Yang, MD, PhD
Contact
jhysmc@gmail.com
82-2-3410-3419

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion